Changes in Renal Function in Patients with Recurrence of Atrial Arrhythmia after an Initial Catheter Ablation

Table 1

Clinical characteristics at baseline during the initial admission before RFCA.

N = 132
Age (years)	62.8 ± 0.7
Men, n (%)	88 (66.7)
AF type- paroxysmal, n (%)	72 (54.5)
AF duration (months)	75.1 ± 6.5
Comorbidities
Congestive heart failure, n (%)	2 (1.5)
Hypertension, n (%)	81 (61.4)
Diabetes mellitus, n (%)	11 (8.3)
Stroke, n (%)	7 (5.3)
Vascular disease, n (%)	0
Coronary artery disease, n (%)	1 (8.3)
Cardiovascular ICD, n (%)	4 (3.0)
CHA2DS2-VASc score	1.7 ± 0.1
Drug therapy
ACEI/ARB, n (%)	62 (47.0)
β-blockers, n (%)	47 (35.6)
CCB, n (%)	29 (22.0)
Diuretics, n (%)	13 (9.8)
OAC-warfarin, n (%)	59 (44.7)
OAC-NOACs, n (%)	33 (25.0)
eGFR at baseline	78.0 ± 0.7
Echocardiographic parameters
LVEF (%)	64.8 ± 0.4
LAD (mm)	39.0 ± 0.5
LVDd (mm)	47.2 ± 0.5

Continuous variables are expressed as the mean ± SD or median and interquartile range (IQR) if nonnormally distributed. Categorial variables are presented as numbers (percentages). AF, atrial fibrillation; ICD, implantable electronic device; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; OACs, oral anticoagulants; NOACs, nonvitamin K antagonist oral anticoagulants; eGFR, estimated glomerular filtration rate; LAD, left atrium diameter; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; LVDd, left ventricular diastolic diameter.